| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S2213-8587(20)30313-2 |
| P698 | PubMed publication ID | 32971040 |
| P2093 | author name string | Thomas Hansen | |
| Peter Rossing | |||
| Tina Vilsbøll | |||
| Lawrence A Leiter | |||
| Jochen Seufert | |||
| Steven P Marso | |||
| Johannes F E Mann | |||
| Thomas Idorn | |||
| Sayeh Tadayon | |||
| P2860 | cites work | Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control | Q26750746 |
| Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q34540403 | ||
| Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis | Q35903126 | ||
| Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials | Q36330921 | ||
| Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers | Q36851156 | ||
| Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate | Q37334515 | ||
| Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes | Q38412125 | ||
| Liraglutide and Renal Outcomes in Type 2 Diabetes | Q40065123 | ||
| Diabetic Nephropathy: a Tangled Web to Unweave | Q41993558 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial | Q46854681 | ||
| Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects | Q47134445 | ||
| Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. | Q48107987 | ||
| Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial | Q49350947 | ||
| Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. | Q53084508 | ||
| Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. | Q53372791 | ||
| Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentr | Q53399727 | ||
| SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials | Q61458485 | ||
| Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | Q63170509 | ||
| The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. | Q64922464 | ||
| Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. | Q64953982 | ||
| The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential | Q86577408 | ||
| Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial | Q89128962 | ||
| Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials | Q89222806 | ||
| Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease | Q90051116 | ||
| Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials | Q90923553 | ||
| Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials | Q91009119 | ||
| The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial | Q91614830 | ||
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial | Q92688468 | ||
| Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial | Q92731317 | ||
| Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial | Q94519099 | ||
| P921 | main subject | type 2 diabetes | Q3025883 |
| semaglutide | Q27261089 | ||
| P577 | publication date | 2020-09-21 | |
| P1433 | published in | The Lancet: Diabetes & Endocrinology | Q27725107 |
| P1476 | title | Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials |
| Q99708015 | Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role? |
| Q102220349 | Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence |
Search more.